APA
Click to copy
Albott, C. S., Lim, K. O., Forbes, M. K., Erbes, C., Tye, S. J., Grabowski, J. G., … Shiroma, P. R. (2018). Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression. Journal of Clinical Psychiatry, 79(3). https://doi.org/10.4088/JCP.17m11634
Chicago/Turabian
Click to copy
Albott, C.S., K.O. Lim, M.K. Forbes, C. Erbes, S.J. Tye, J.G. Grabowski, P. Thuras, T.M. Batres-Y-Carr, J. Wels, and P.R. Shiroma. “Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.” Journal of Clinical Psychiatry 79, no. 3 (2018).
MLA
Click to copy
Albott, C. S., et al. “Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.” Journal of Clinical Psychiatry, vol. 79, no. 3, 2018, doi:10.4088/JCP.17m11634.
BibTeX Click to copy
@article{albott2018a,
title = {Efficacy, safety, and durability of repeated ketamine infusions for comorbid posttraumatic stress disorder and treatment-resistant depression},
year = {2018},
issue = {3},
journal = {Journal of Clinical Psychiatry},
volume = {79},
doi = {10.4088/JCP.17m11634},
author = {Albott, C.S. and Lim, K.O. and Forbes, M.K. and Erbes, C. and Tye, S.J. and Grabowski, J.G. and Thuras, P. and Batres-Y-Carr, T.M. and Wels, J. and Shiroma, P.R.}
}
Objective: The present study examined the efficacy, safety, and durability of repeated ketamine infusions for the treatment of comorbid posttraumatic stress disorder (PTSD) and treatment-resistant depression (TRD) in a sample of veterans.
Methods: Individuals with comorbid DSM-5-defined PTSD and DSM-IV-defined major depressive disorder (N = 15) received 6 intravenous ketamine infusions (0.5 mg/kg) on a Monday-Wednesday-Friday schedule over a 12-day period from May 2015 to June 2016. Data from outcome measures were collected before and 24 hours after each infusion and weekly for 8 weeks following the final infusion.
Results: Continuous measures of symptom change were significant for both disorders and were associated with large effect sizes (mean decrease in PTSD Checklist for DSM-5 score = 33.3 points [95% CI, 23.0-43.5 points], P < .0005, sample size-adjusted Cohen d [d'] = 2.17; mean decrease in Montgomery-Asberg Depression Rating Scale score = 26.6 points [95% CI, 23.0-30.2 points], P < .0005, d' = 4.64). The remission rate for PTSD was 80.0%, and the response rate for TRD was 93.3%. Participants in remission from PTSD after the infusion series (n = 12) had a median time to relapse of 41 days. Similarly, participants whose depression symptoms responded to the infusion series (n = 14) had a median time to relapse of 20 days. Repeated ketamine infusions were associated with transient increases in dissociative symptoms. No participant reported worsening of PTSD symptoms over the study duration.
Conclusions: This study, the first open-label study of repeated ketamine infusions in a comorbid population, found rapid and sustained improvement in PTSD and depression symptoms. This report suggests that repeated ketamine treatments are safe and may represent an efficacious treatment for individuals with comorbid PTSD and TRD.
